Efficacy and safety of hypofractionated versus conventional radiotherapy in breast cancer: a systematic review and meta-analysis - Takeaways - MDSpire

Efficacy and safety of hypofractionated versus conventional radiotherapy in breast cancer: a systematic review and meta-analysis

  • By

  • Malek Talal

  • Marafi Jammaa Ahmed

  • Muhammad M. Elsharkawy

  • Alaa R. AL-Ihribat

  • Mohamed F. Srour

  • Youssef Z. Farhat

  • Muhammad Youssef

  • Rabeia Babiker Mustafa

  • Mohamed Wafa

  • Ahmed Werdany Hassan

  • Aya Ahmed Shimal

  • Omran Shrebaty

  • Ibrahim Moqbel

  • May 13, 2026

  • 0 min

Share

  • 1

    Hypofractionated whole-breast irradiation (HFRT) offers similar oncological outcomes to conventional fractionated radiotherapy (CFRT) in early-stage breast cancer.

  • 2

    The meta-analysis included eight studies with 5,495 patients, showing no significant difference in disease-free survival between HFRT and CFRT.

  • 3

    HFRT demonstrated a trend toward reduced acute radiation dermatitis compared to CFRT, although results showed substantial heterogeneity across studies.

  • 4

    No significant difference in lymphedema incidence was found between HFRT and CFRT, indicating comparable safety profiles.

  • 5

    Future research should focus on standardizing radiation treatments and evaluating long-term toxicity and patient-reported outcomes.

Original Source(s)

Efficacy and safety of hypofractionated versus conventional radiotherapy in breast cancer: a systematic review and meta-analysis

  • by Malek Talal, Marafi Jammaa Ahmed, Muhammad M. Elsharkawy, Alaa R. AL-Ihribat, Mohamed F. Srour, Youssef Z. Farhat, Muhammad Youssef, Rabeia Babiker Mustafa, Mohamed Wafa, Ahmed Werdany Hassan, Aya Ahmed Shimal, Omran Shrebaty, Ibrahim Moqbel

  • May 13, 2026

Related Content

Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells

Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin

Editorial: Epigenetic modulation in cancer